Ophthalmic Business

Top Story

Roclatan meets primary efficacy endpoint in phase 3 study

May 25, 2017

Roclatan, a once-daily fixed-dose combination drug for lowering IOP, has achieved its primary efficacy endpoint in the Mercury 2 phase 3 study, Aerie Pharmaceuticals announced in a press release.

The 90-day trial compared Roclatan — a combination of Rhopressa (netarsudil ophthalmic solution 0.02%) and latanoprost — with monotherapy of each of its components. IOP was measured three times daily at 2 weeks, 6 weeks and 90 days. Roclatan reduced IOP between 1.5 mm Hg and 2.4 mm Hg more than latanoprost alone and between 2.2 mm Hg and 3.3 mm Hg more than Rhopressa alone, the release said.

ClearSight’s parent company acquired by China-based firm

May 25, 2017
Sharklet Technologies, the parent company of ClearSight, has been acquired by the China-based equity medical device firm Peaceful Union, ClearSight announced in a press…

AGTC posts first-quarter net loss of $0.8 million

May 24, 2017
Applied Genetic Technologies Corporation reported a net loss of $0.8 million in the first quarter of 2017 compared with a net income of $2 million in the same period of…

Iridex reports $10.5 million in quarterly revenue

May 24, 2017
Iridex reported revenue of $10.5 million in the first quarter of 2017 compared with revenue of $11.9 million in the same time period last year, according to a company…
Original Article

Progression of High Anisometropia in Children

Journal of Pediatric Ophthalmology and Strabismus
Online Advanced Release, May 17, 2017
To investigate the onset and rate of progression of high anisometropia in myopic children younger than 13 years. A…
More »
CME

Treating Advanced Dry Age-related Macular Degeneration and Geographic Atrophy: Here and Now

This activity is supported by an educational grant from Allergan, Inc.

Dry eye disease (DED) is a condition of the ocular surface in which multiple factors are responsible for the…
More »
Featured
Video

Genentech completes enrollment in two phase 3 lampalizumab studies

February 2, 2017
More »

Roclatan meets primary efficacy endpoint in phase 3 study

May 25, 2017
Roclatan, a once-daily fixed-dose combination drug for lowering IOP, has achieved its primary efficacy endpoint in the

ClearSight’s parent company acquired by China-based firm

May 25, 2017
Sharklet Technologies, the parent company of ClearSight, has been acquired by the China-based equity medical device firm Peaceful Union, ClearSight…

AGTC posts first-quarter net loss of $0.8 million

May 24, 2017
Applied Genetic Technologies Corporation reported a net loss of $0.8 million in the first quarter of 2017 compared with a net income of $2 million in…

Iridex reports $10.5 million in quarterly revenue

May 24, 2017
Iridex reported revenue of $10.5 million in the first quarter of 2017 compared with revenue of $11.9 million in the same time period last year…

Two iStent procedure may be more cost-efficient than other IOP-lowering treatments

May 23, 2017
In treating elevated IOP in open-angle glaucoma patients, two iStent trabecular micro-bypass stents had a lower projected cumulative cost after 5…

Lensar, PDL BioPharma announce restructuring plan

May 22, 2017
Lensar will become a wholly owned subsidiary of PDL BioPharma through a financial restructuring plan that has been court approved, according to a…

Omeros reports $15.1 million quarterly net loss

May 22, 2017
Omeros reported a net loss of $15.1 million, or $0.34 per share, in the first quarter of 2017 compared with a net loss of $20.5 million, or $0.54 per…

Alcon names chief medical officer

May 19, 2017
Stephen S. Lane, MD, will join Alcon as its chief medical officer and global head of franchise clinical strategy, where he will lead the integration…

SightLife Surgical names P. Bernard Haffey chief commercial officer

May 19, 2017
Paul Bernard “Bernie” Haffey has joined SightLife Surgical as its first chief commercial officer, according to a company press release. …

From OSN Europe

Precizon Presbyopic IOL from Ophtec receives CE mark

May 18, 2017
The aspheric Precizon Presbyopic IOL received a CE mark and will be commercially launched in October during the European Society of Cataract and…

More Headlines »
Advertisement
Advertisement